Atezolizumab in advanced non-small cell lung cancer
- PMID: 29268352
- PMCID: PMC5723868
- DOI: 10.21037/jtd.2017.09.73
Atezolizumab in advanced non-small cell lung cancer
Conflict of interest statement
Conflicts of Interest: Paul Hofman is a member of different industrial scientific advisory boards (Roche, AstraZeneca, Novartis, Bristol-Myers Squibb, Pfizer, Qiagen, Janssen, Biocartis) for which he receives honorarium. Marius Ilié has no conflicts of interest to declare.
Comment on
-
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13. J Clin Oncol. 2017. PMID: 28609226 Free PMC article. Clinical Trial.
Similar articles
-
Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.Int J Clin Pharm. 2020 Aug;42(4):1175-1183. doi: 10.1007/s11096-020-01076-3. Epub 2020 Jun 11. Int J Clin Pharm. 2020. PMID: 32524512 Clinical Trial.
-
The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.Cancer Biomark. 2018;22(3):467-476. doi: 10.3233/CBM-171089. Cancer Biomark. 2018. PMID: 29758930
-
Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.Front Immunol. 2022 Jun 21;13:909027. doi: 10.3389/fimmu.2022.909027. eCollection 2022. Front Immunol. 2022. PMID: 35799785 Free PMC article.
-
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer.Front Biosci (Schol Ed). 2021 Dec 3;13(2):190-201. doi: 10.52586/S562. Front Biosci (Schol Ed). 2021. PMID: 34879471 Review.
-
Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.Target Oncol. 2018 Jun;13(3):399-407. doi: 10.1007/s11523-018-0570-5. Target Oncol. 2018. PMID: 29785577 Review.
Cited by
-
Recent advances in non-small cell lung cancer targeted therapy; an update review.Cancer Cell Int. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y. Cancer Cell Int. 2023. PMID: 37568193 Free PMC article. Review.
-
A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.Adv Exp Med Biol. 2021;1286:49-64. doi: 10.1007/978-3-030-55035-6_3. Adv Exp Med Biol. 2021. PMID: 33725344 Review.
-
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.Lung Cancer Manag. 2019 May 7;8(2):LMT11. doi: 10.2217/lmt-2018-0016. eCollection 2019 Oct. Lung Cancer Manag. 2019. PMID: 31645894 Free PMC article.
-
Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer.Lung Cancer Manag. 2019 May 9;4(6):LMT12. doi: 10.2217/lmt-2019-0001. eCollection 2019 Oct. Lung Cancer Manag. 2019. PMID: 31645892 Free PMC article.
-
Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.J Am Acad Dermatol. 2018 Dec;79(6):1047-1052. doi: 10.1016/j.jaad.2018.05.035. Epub 2018 May 29. J Am Acad Dermatol. 2018. PMID: 29857011 Free PMC article.
References
-
- Hanna N, Johnson D, Temin S, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;JCO2017746065. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources